Alx Oncology Holdings (ALXO) Change in Accured Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Change in Accured Expenses data on file, last reported at -$3.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 3005.15% year-over-year to -$3.0 million; the trailing twelve-month figure through Mar 2026 stood at -$913000.0 (up 92.16% YoY), and the FY2025 full-year result was $2.0 million, up 115.86% from the prior year.
• Change in Accured Expenses fell to -$3.0 million in Q1 2026, from -$2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.3 million in Q3 2023 to a low of -$10.9 million in Q4 2024.
• A 5-year average of $271588.2 and a median of -$97000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 669.59% in 2023 and plunged 3005.15% in 2026, its largest moves.
• Tracing ALXO's Change in Accured Expenses over 5 years: stood at $615000.0 in 2022, then jumped by 669.59% to $4.7 million in 2023, then slumped by 330.17% to -$10.9 million in 2024, then jumped by 80.28% to -$2.1 million in 2025, then tumbled by 40.22% to -$3.0 million in 2026.
• Business Quant data shows ALXO's Change in Accured Expenses at -$3.0 million in Q1 2026, -$2.1 million in Q4 2025, and $6.2 million in Q3 2025.